Anti-Parathyroid Agent

4 Drugs classified under this drug class

Anti-Parathyroid Agent. Cinacalcet (as HCl) 30, 60, 90 mg.
F.C. TABS.: 28×30, 60, 90 mg. For hyperparathyroidism: init. dosage is 30 mg (one tab.) ×1/d.
For parathyroid cancer or prim. hyperparathyroidism: init. dosage is 30 mg (one tab.) ×2/d. Should be taken with food.
Tmt. of second. hyperparathyroidism (HPT) in pts. with end-stage ren. dis. (ESRD) on maint. dialysis ther.
May be used as part of a therap. regimen includ. phosphate binders and/or Vitamin D sterols, as appropr.
Reduct. of hypercalcaemia in pts. with parathyroid carcinom.
Reduct. of hypercalcaemia in pts. with:
Parathyroid carcinoma.
Prim. HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant tmt. guidelines), but in whom parathyroidectomy is not clinical. appropriate or is contraindic.
C/I: Hypersens.

Anti-Parathyroid Agent. Cinacalcet (as HCl) 30, 60, 90 mg.
TABS.: 30×60, 30 mg, 28×90 mg. Hyperparathyroidism (usual start. dose): 30 mg ×1/d.
Parathyroid cancer, primary hyperparathyroidism (usual start. dose):30 mg×2/d.
Tmt. of secondary HPT in ESRD on mainten. dialysis ther. May be used as part of a therap. regimen includ. phosphate binders and/or Vit. D sterols, as appropriate. Reduct. of hypercalcaemia in pts. with parathyroid carcinoma. Reduct. of hypercalcaemia in pts. with: Parathyroid Carcinoma, Primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant tmt. guidelines), but in whom parathyroidectomy is not clinic. appropriate or contraindic.
C/I: Hypersens.

Anti-Parathyroid Agent. Cinacalcet 30, 60, 90 mg.
F.C. TABS.: 14, 28, 30, 84. Usual start. is 30 mg, once per day. Parathyroid cancer/ prim. hyperparathyroidism: usual start. dose is 30mg×2/d with or shortly after food.
Tmt. of second. HPT in pts. with ESRD on maint. dialysis ther. As part of a therap. regimen includ. phosphate binders and/ or vitamin D sterols, as appropriate. Reduct. of hypercalcaemia in pts. with:
Parathyroid carcinoma, Primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinical. appropriate or is contraindicated.
C/I: Hypersens.

Anti-Parathyroid Agent. Etelcalcetide 5 mg/ml.
VIAL (Sol. for inj.): 6×0.5,1,2. The recomm. init. dose of etelcalcetide is 5 mg admin. by bolus inj. 3 times/wk. Corrected serum calcium should be at or above the lower limit of the normal range prior to admin. of first dose of etelcalcetide, a dose incr., or reinitiation after a dose stop (see also dose adjust. based on serum calcium levels). Etelcalcetide should not be admin. more frequen. than 3 times/wk.
Dose titration: Etelcalcetide should be titrated so that doses are individ. betwn. 2.5 mg and 15 mg. The dose may be incr. in 2.5 mg or 5 mg increm. no more frequent. than every 4 wks. to a max. dose of 15 mg 3 times/wk. to achieve the desired parathyroid hormone (PTH) target.
Dose adjust. based on PTH levels: PTH should be measured after 4 wks. from init. or dose adjust. of etelcalcetide, and approx. every 1-3 mnths. during mainten. Dose adjust. may be necessary at any time during tmt. includ. the maintenan. phase. See lit.
Treatment of secondary hyperparathyroidism (SHPT) in adult patients with chron. kidney disease (CKD) on hemodialysis ther.
C/I: Hypersens. Pts. with level of the calcium less than the lower limit of the normal range.